SCHEMBL6562398

SCHEMBL6562398

O=C(O)c1ccccc1-c1ccc(C(F)(F)F)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.54
PDK2 Q15119 2/20 0.51
FABP4 P15090 4/20 0.49
RORC P51449 2/20 0.49
RORB Q92753 1/20 0.49
SCN9A Q15858 1/20 0.48
CLCN2 P51788 1/20 0.48
NOTUM Q6P988 1/20 0.47
FABP3 P05413 1/20 0.47
EIF4E P06730 1/20 0.46
PSD A5PKW4 1/20 0.44
AKR1C3 P42330 1/20 0.44
AKR1C2 P52895 1/20 0.44
RAB9A P51151 1/20 0.44
ALDH1A1 P00352 1/20 0.43
P2RX7 Q99572 1/20 0.43
KLRK1 P26718 1/20 0.43
MICA Q29983 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3542609 0.81 PTGER1 (0.56) PDK2RORBEIF4EAKR1C3AKR1C2
SCHEMBL31161066 0.80 CHRM1 (0.53) KMOPDK2FABP4FABP3EIF4E
SCHEMBL6562403 0.79 KMO (0.45) KMOFABP4SCN9AAKR1C3AKR1C2
SCHEMBL4881566 0.78 ALDH1A1 (0.58) PDK2EIF4EAKR1C2RAB9AALDH1A1
SCHEMBL23354547 0.77 FTO (0.53) KMOPDK2EIF4EAKR1C2ALDH1A1
SCHEMBL6639868 0.76 PRKAB2 (0.44) KMOPDK2FABP4RORCRORB
SCHEMBL1041026 0.76 ESR2 (0.52) KMOPDK2
Xenalipin SCHEMBL29881739 0.74 CYP2C8 (0.58) KLRK1MICA
Xenalipin SCHEMBL133087 0.74 CYP2C8 (0.58) KLRK1MICA
SCHEMBL22452977 0.74 TAS2R14 (0.55) FABP4CLCN2AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 US disclosed
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-3822268-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2021-05-19 EP disclosed
EP-1223158-B1 Process for preparing trifluoromethyl substituted biphenyl carboxylic acids and novel trichloromethyl and trifluoromethyl substituted biphenyl nitriles BAYER CHEMICALS AG (DE) 2004-08-11 EP disclosed
US-6580002-B2 Dihalo-, cyano- and methyl- substituted biphenyl chemical intermediates BAYER AKTIENGESELLSCHAFT (DE) 2003-06-17 US disclosed
US-20030055285-A1 Process for the preparation of trifiuoromethyl-substituted biphenylcarboxylic acids and novel trichloromethyl-and trifluoromethyl-substituted biphenylcarbonitriles LANXESS DEUTSCHLAND GMBH (DE) 2003-03-20 US disclosed
US-6465688-B2 CONVERTING METHYL-SUBSTITUTED BIPHENYLCARBONITRILES TO A TRICHLOROMETHYL- AND HYDROLYZING TO CORRESPONDING CARBOXY ACIDS BAYER AKTIENGESELLSCHAFT (DE) 2002-10-15 US disclosed
US-20020095052-A1 PROCESS FOR THE PREPARATION OF TRIFLUOROMETHYL-SUBSTITUTED BIPHENYLCARBOXYLIC ACIDS AND NOVEL TRICHLOROMETHYL - AND TRIFLUOROMETHYL - SUBSTITUTED BIPHENYLCARBONITRILES LANXESS DEUTSCHLAND GMBH (DE) 2002-07-18 US disclosed
EP-1223158-A1 Process for preparing trifluoromethyl substituted biphenyl carboxylic acids and novel trichloromethyl and trifluoromethyl substituted biphenyl nitriles Bayer Aktiengesellschaft (DE) 2002-07-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 KMO 728/4885PDK2 2446/4885FABP4 4725/4885
US-20030055285-A1 Process for the preparation of trifiuoromethyl-substituted biphenylcarboxylic acids and novel trichloromethyl-and trifluoromethyl-substituted biphenylcarbonitriles CPSF1, CYP2F1, CYP4F2 KMO 122/4885PDK2 1279/4885FABP4 766/4885
US-20020095052-A1 PROCESS FOR THE PREPARATION OF TRIFLUOROMETHYL-SUBSTITUTED BIPHENYLCARBOXYLIC ACIDS AND NOVEL TRICHLOROMETHYL - AND TRIFLUOROMETHYL - SUBSTITUTED BIPHENYLCARBONITRILES MCCC2, CYP2F1, CYP4F2 KMO 82/4885PDK2 1167/4885FABP4 477/4885
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 KMO 728/4885PDK2 2446/4885FABP4 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.